Download PDF
Horm Metab Res 1976; 8(2): 88-91
DOI: 10.1055/s-0028-1093678
Originals

© Georg Thieme Verlag KG Stuttgart · New York

Clinical Evaluation of a New Sulfonylurea in Maturity Onset Diabetes - Glipizide (K-4024)

M. S. Bandisode , B. R. Boshell
  • Department of Medicine, Division of Endocrinology and Metabolism, Diabetes Research and Education Hospital, University of Alabama in Birmingham, USA
Further Information

Publication History

Publication Date:
23 December 2008 (online)

Also available at
  PDF Download  Permissions and Reprints

Abstract

Glipizide, a new low dose sulfonylurea, was evaluated for its efficacy and toxicity in a double-blind controlled study. Forty adult-onset diabetics were treated with either chlorpropamide or glipizide. In ten out of twenty patients "excellent" to "good" control of hyperglycemia was achieved with glipizide and two patients evidenced "fair" control. In nine out of eighteen patients "excellent" to "good" control was achieved with chlorpropamide. Eight of the sixteen patients who were primary or secondary failures on the two drugs responded to glipizide and phenformin combination with "excellent" to "good" control. No therapeutic advantage was found in giving more than 25 mg/day glipizide in ten patients. Toxicity was low and side effects were uncommon over a period of 26 months.

Key words

Glipizide (K-4024) - New Oral Hypoglycemia Agent - Clinical Evaluation of - Comparison with Chlorpropamide